Antihistamines

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Johannes Trueck, Medisch Centrum Leeuwarden

Conditions

ADHD attention deficit and hyperactivity disorderAllergy in ChildrenAnaphylactic ReactionAnaphylaxisCarcinoma, Small CellHairy Cell LeukemiaIgE Mediated Food AllergyLung Cancer

Phase 1

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

CompletedNCT03554473

National Cancer Institute (NCI)Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer

Start: 2018-09-11End: 2025-03-13Updated: 2025-05-09

Phase 2

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Active, not recruitingNCT01059786

National Cancer Institute (NCI)Hairy Cell Leukemia

Start: 2010-07-01End: 2027-12-31Updated: 2025-06-12

Phase 4

Systemic antihistamines in the treatment of attention-deficit/hyperactivity disorder (ADHD): a pilot study.

Medisch Centrum LeeuwardenADHD attention deficit and hyperactivity disorder

Target: 60Updated: 2024-02-28

Steroid Use in Treatment of Allergic Reactions to Food

RecruitingNCT07341776

Johannes TrueckAllergy in Children, Anaphylactic Reaction, Anaphylaxis +1

Start: 2026-01-26End: 2026-12-01Target: 160Updated: 2026-01-27

Related Papers

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.

2025-10-08

Abstract 3771: Non invasive monitoring of relapsed SCLC using cell free fragmentomes and peripheral blood immunophenotyping

Cancer Research2025-04-21

Abstract CT257: Hyperprogressive disease following bintrafusp alfa and DNA damaging chemotherapy in relapsed small cell lung cancer

Cancer Research2024-04-05